Please ensure Javascript is enabled for purposes of website accessibility

Is Inovio Pharmaceuticals Stock a Buy?

By Prosper Junior Bakiny – Aug 13, 2020 at 8:33AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Could this biotech stock be a major winner down the road?

Investing in clinical-stage biotech companies isn't for the faint of heart. Negative results from clinical trials or regulatory roadblocks can send shares of these companies plunging. On the other hand, investing in the right clinical-stage biotech stock can reap life-changing returns, particularly if the company in question develops a vaccine for an infectious disease that has spread across the world and has killed thousands of people. 

One company that could go on to do just that is Inovio Pharmaceuticals (INO). The biotech has been racing through the early stages of the development of its investigational coronavirus vaccine, INO-4800. As a result, Inovio's stock is up by 343.3% year to date as of this writing. Before pulling the trigger on this biotech stock, though, let's take a closer look at what's really going on with Inovio Pharmaceuticals. 

INO Chart

INO data by YCharts

Inovio's COVID-19 program

More than a dozen companies are looking to develop vaccines for the novel coronavirus, and that's a good thing. Given the worldwide need for an effective way to prevent new infections, it is unlikely that just one company will be able to fill this need.

In other words, even if the field is crowded, a vaccine could still be highly lucrative for Inovio. The company could cash in on this opportunity if INO-4800 proves as or more effective than its competitors, or if INO-4800 makes it to the market before most of its peers in this race.

Could Inovio meet one -- or both -- of these conditions? It seems unlikely. The company did report that during INO-4800's phase 1 clinical trial, all the participants developed immune responses, with almost 90% of them generating strong T-cell responses. T-cells are white blood cells that bind to and kill antigens, or harmful molecules. Also, Inovio found that its candidate proved effective at preventing infection by SARS-CoV-2 -- the virus that causes COVID-19 --  in nonhuman primates 13 weeks after they were last vaccinated.

Piggy bank wearing a face mask.

Image source: Getty Images.

With that said, other companies have also reported impressive results. My own opinion is that AstraZeneca (AZN -0.32%) and Pfizer (PFE -0.32%) have the most promising vaccine candidates so far. It is hard to know yet whether Inovio's candidate is definitively superior to those of its peers. But we do know that while both AstraZeneca and Pfizer (among others) have already started phase 3 studies, Inovio has yet to do the same. The company is hoping to start a phase 2/3 clinical trial for INO-4800 this summer, though, and it could still end up being one of the winners in this race.

Between the uncertainty surrounding clinical trials and potential regulatory roadblocks, lots of things could happen that might flip this race on its head. However, it is hard to justify investing in Inovio solely for its coronavirus vaccine program, as opposed to other companies that have produced impressive clinical trial results and are further along in their efforts. 

Looking at the rest of Inovio's pipeline

Inovio's most advanced pipeline candidate is VGX-3100, a potential vaccine for HPV-related precancerous cervical dysplasia. The company is currently running a phase 3 clinical trial for this medicine. Further, the U.S. Food and Drug Administration (FDA) recently granted the orphan drug designation to Inovio's INO-3107, a potential vaccine for HPV-related recurrent respiratory papillomatosis. This medicine is currently in a phase 2 clinical trial.

Inovio has other promising pipeline candidates, all of which are still in phase 1 or phase 2 testing. The company also has quite a few partners, including biotech giants such as Regeneron (REGN -1.53%) and organizations such as the Coalition for Epidemic Preparedness Innovations. Crucially, though, none of the company's candidates are anywhere close to receiving FDA approval.

What's the verdict?

In my view, Inovio isn't the most promising company for investors seeking exposure to the coronavirus vaccine race. Also, while the company does have several promising candidates, putting INO-4800 aside, Inovio likely won't launch a drug on the market for another two years or so. Given these factors, I don't think Inovio's stock is a buy right now. But investors should keep an eye on this biotech stock, as its fortunes could change quickly. 

Prosper Junior Bakiny has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Inovio Pharmaceuticals Stock Quote
Inovio Pharmaceuticals
$1.90 (%)
Pfizer Stock Quote
$49.41 (-0.32%) $0.16
AstraZeneca PLC Stock Quote
AstraZeneca PLC
$66.00 (-0.32%) $0.21
Regeneron Pharmaceuticals Stock Quote
Regeneron Pharmaceuticals
$730.11 (-1.53%) $-11.37

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 11/29/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.